Increasing equity in lung cancer screening
NCT ID NCT06360822
First seen Sep 10, 2026 · Last updated Sep 10, 2026
Summary
The overall objective of this mixed methods study is to: 1) Refine the Emergency Department Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key stakeholders; 2) pilot test the ED-LCS intervention evaluating the intervention efficacy, acceptability, and feasibility; and 3) provide an in-depth description of stakeholders' experiences with the ED-LCS intervention for future refinement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 144 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2023
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * • Eligible for LCS (50-80 years old, smoked in past 15 years, and smoked at least 20 pack years) Exclusion Criteria: * • Non-English/Spanish speaking * Decompensated psychiatric illness (suicidal, homicidal, psychosis). Will confirm with attending physicians at time of enrollment * Intoxicated with alcohol or drugs * Cannot provide reliable follow up contact information (cell phone) * Presenting to the ED with a life-threatening condition * Have received chest CT scan in past 12 months * Already enrolled in LCS * Hospice enrolled
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Eskenazi Health
RECRUITINGIndianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A dose-escalation, dose-extension and efficacy-extension, phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of AP-L1898 capsule for the treatment of the patients with locally advanced or metastatic non-small cell lung cancer
- Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide
- A spoonful of olive oil before lung surgery: a new shield against a rare complication?
- Mobile lung cancer clinics aim to close rural screening gap
- Can protein patterns in stored tumors point to new treatment targets?
- Lung surgery without a breathing tube: a gentler path to recovery?